Document is current
Any future updates will be listed below
-
Authors
Clausen, Thomas Mandel
Kumar, Gunjan
Ibsen, Emilie K.
Ørum-Madsen, Maj S.
Hurtado-Coll, Antonio
Gustavsson, Tobias
Agerbæk, Mette Ø.
Gatto, Francesco
Todenhöfer, Tilman
Basso, Umberto
Knowles, Margaret A.
Sanchez-Carbayo, Marta
Salanti, Ali
Black, Peter C.
Daugaard, Mads https://orcid.org/0000-0001-8383-055X
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research ((FRN: 153092))
European Research Council MalOnco program Kirsten and Freddy Foundation Harboe Foundation Sofus Carl Emil Friis og hustru Olga Doris Friis Foundation
- License Information
-
More Information
Article History
Received: 9 June 2020
Revised: 29 June 2020
Accepted: 13 July 2020
First Online: 27 July 2020
Conflict of interest
: T.M.C., A.S., M.Ø.A., and M.D. are shareholders in VAR2 Pharma that holds the intellectual property for using rVAR2 technology to diagnose cancer. M.Ø.A. has received salary support from VarCT Diagnostics. The remaining authors declare no conflicts of interest with the contents of this article.
